Precision-health AI platform spun out of Alphabet/Google X — runs the Verily Pre clinical-research platform and Onduo virtual-care services
Healthcare📍 Dallas, TXFounded 2015
Current Valuation
$5.0B
as of 2026-Q1
UNICORN
IPO Outlookprivate
Is Verily going public?
No. Verily has no imminent IPO plans on record. It is still private.
What is Verily's valuation in 2026?
Verily is valued at $5.0B as of 2026-Q1, set by its Strategic recapitalization ($300M, Mar 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Verily filed an S-1?
No public S-1 is on file for Verily.
Who are Verily's investors?
Verily's investors include Series X Capital, Alphabet (minority post-2026), UCHealth, University of Colorado Anschutz, Silver Lake, Temasek and 1 more.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Verily (formerly Google Life Sciences, renamed Verily in December 2015) is a precision-health AI company that began as a research unit inside Google X and was spun into an Alphabet subsidiary in 2015 under founding CEO Andrew Conrad. Stephen Gillett (ex-Symantec / Best Buy) took over as CEO in 2023. In March 2026 the company raised a $300M strategic round led by Series X Capital with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and others — a recapitalization that left Alphabet as a significant minority (no longer controlling) investor, effectively spinning Verily out as a stand-alone company. Headquartered in Dallas, TX since August 2024 (moved from South San Francisco). Operates the Verily Pre clinical-research platform, Onduo virtual chronic-care, Project Baseline, and Liftware; recently signed partnerships with Samsung Galaxy Watch and Salesforce Agentforce Health. 2022 revenue of $559M against a $568M operating loss; total raised across Series A-C (Silver Lake, Temasek, SoftBank) plus the 2026 recap is ~$3.3B. Valuation reportedly written down ~80% from 2022 peak (~$23B) per The Information and Business Insider, putting the post-recap value in the $4-5B range.
Company Profile
CEO
Stephen Gillett
Founded
2015
HQ
Dallas, TX
Employees
~1100
Total Raised
$3.3B
Est. Revenue
$559M (2022-Q4)
Growth
Restructuring — revenue $559M (2022) with $568M operating loss; post-2026 recap is a relaunch under Series X Capital
Last Round
Strategic recapitalization — $300M (Mar 2026) · Lead: Series X Capital
IPO Status
no imminent plans
Fundraising Status
Strategic recapitalization · $300M · 5 mo ago
no imminent plansTotal raised $3.3B
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Strategic recapitalization
$300M
Mar 2026
Series X Capital
—
Vertical Intelligence — AI / ML
No verified Hugging Face organization found for Verily — no attributable open-model footprint. Closed-weights labs are common; this is a distribution signal, not a capability judgment.
Checked huggingface.co as of 2026-08-19. Re-checked weekly.
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
65
via workday
Product-build share
62%
engineering, research, product, design
Trajectory
steady
product-led hiring — 62% of open roles build product; the rest are go-to-market and G&A.
Counted from Verily's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Andrew Conrad
Investors
Series X Capital · Alphabet (minority post-2026) · UCHealth · University of Colorado Anschutz · Silver Lake · Temasek · SoftBank Vision Fund
Products
Verily Pre Platform (precision-health AI for life-sciences research)
Onduo (virtual chronic-disease care)
Liftware (assistive eating utensils)
Project Baseline (longitudinal health study)
Competitors
Tempus AI · Flatiron Health (Roche) · Komodo Health · Truveta · OneStudyTeam (CRO infrastructure) · Iqvia
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q1. Refreshed quarterly.